Couldn't agree more. GSK are now trying to clean up their image by supporting the priniciple of open data sharing in the future, but firms caught doing the things they have should be made to disclose their entire retrospective research databases for independent scrutiny at their own cost, as well as being made open to the prosecution of individuals involved in fraud/false marketing/data concealment.

It is shameful that settlements like this can be part of a business plan to amass huge profits while knowingly harming patients. As yet there is nothing concrete in place to deter similar behaviour in the future.

Richard
From: Evidence based health (EBH) [[log in to unmask]] on behalf of Paul Elias [[log in to unmask]]
Sent: Tuesday, July 03, 2012 9:03 AM
To: [log in to unmask]
Subject: GlaxoSmithKline to pay $3B in largest healthcare fraud settlement in US history

Once again, the good, the bad, the ugly about big pharma...for this, I can only see the bad and ugly, nothing good about this. this was all greed and complicity. Last week it was Pfizer and the Celebrex deceit and witholding of safety clinical data, now Glaxo...

 
 
 
 
Best,

Paul E. Alexander